GB2534153A - Method and device for the treatment of diseases - Google Patents
Method and device for the treatment of diseases Download PDFInfo
- Publication number
- GB2534153A GB2534153A GB1500555.6A GB201500555A GB2534153A GB 2534153 A GB2534153 A GB 2534153A GB 201500555 A GB201500555 A GB 201500555A GB 2534153 A GB2534153 A GB 2534153A
- Authority
- GB
- United Kingdom
- Prior art keywords
- operating space
- gas mixture
- treatment
- patient
- gaseous mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 18
- 201000010099 disease Diseases 0.000 title claims description 16
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 239000008246 gaseous mixture Substances 0.000 claims description 14
- 210000002216 heart Anatomy 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010002906 aortic stenosis Diseases 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 230000001360 synchronised effect Effects 0.000 claims description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract description 36
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract description 18
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 abstract description 10
- 239000001569 carbon dioxide Substances 0.000 abstract description 3
- 239000007789 gas Substances 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 7
- 210000001736 capillary Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000035485 pulse pressure Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000545744 Hirudinea Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000002816 chronic venous insufficiency Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0218—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement
- A61H23/0236—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement using sonic waves, e.g. using loudspeakers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
- A61H2033/141—Devices for gas baths with ozone, hydrogen, or the like with ionised gas, e.g. ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
- A61H2033/145—Devices for gas baths with ozone, hydrogen, or the like with CO2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H35/00—Baths for specific parts of the body
- A61H2035/004—Baths for specific parts of the body for the whole body except the head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
- A61H2201/5082—Temperature sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
- A61H2201/5089—Gas sensors, e.g. for oxygen or CO2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
- A61H2201/5092—Optical sensor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2230/00—Measuring physical parameters of the user
- A61H2230/25—Blood flowrate, e.g. by Doppler effect
- A61H2230/255—Blood flowrate, e.g. by Doppler effect used as a control parameter for the apparatus
Abstract
A gas and sound treatment apparatus features a container for a patient which, in use, is filled with gas and sound waves. The gas is a mixture of carbon dioxide and ozone. The apparatus also features details of a control system for the operation of the device.
Description
Description
Title: Method and device for the treatment of diseases
Field of the invention
[0001] The field of the invention relates to a method and device for the treatment of diseases
Background of the invention
[0002] Ion-ozone treatment or ozone treatment of the human body is already known for decades. Cabins are known, which encapsulate the whole human body excluding the head with ozone or a mixture of ozone and carbon dioxide steam. The aim of such a treatment is to achieve a calming effect regarding the blood circulation system and the nervous system.
[0003] A CO, therapy is appropriate for patients suffering from chronic disorders of the aortas, the veins or the capillary system, complications caused by diabetes. Furthermore patients with reparatory vascular operations, sympathectomy and operations using dilata-tion catheter or with stent implantation may benefit from such a therapy. In most cases, the treatment is also appropriate for inoperable patients.
[0004] Among the diseases of the vascular system, chronic venous insufficiency, post-thrombosis syndrome or the disorders of the lymphatic circulation and inertly healing lim-bic ulcers show positive signs after CO2 treatment. Besides loco motoric disease patterns, the results are also excellent with the treatment of post-traumatic complications. Proved effects of carbon dioxide treatment are: more intense fat burning, treatment of cellulites, skin tightening, treatment of balding, treatment of slowly healing wounds and efficient treatment of impotency.
[0005] In the ion-ozone cabin used in ion-ozone therapy either carbonated or ionized water is used, but it is nit intended to use them together at the same time.
Object of the invention [0006] It is an object of the invention to provide a method and device for the treatment of diseases.
Summary of the invention
[0007] The present invention provides a method for the treatment of diseases, comprising the steps of using an operating space for encapsulating at least one patients body excluding the head; providing a gas mixture of CO2 and 03 into the operating space encapsulating the patient, wherein the gas mixture consists of 80 -89% CO2 and 0.1 -5.0 % 03 adding the respective amount of 02 up to 100%; keeping the pressure in the operating space between 0.5 1.5 bar; pumping the gas mixture into the operating space at the rate of 0.4 1.2 litres per second; keeping the gas mixture inside the operating space for a pre-determined period of time.
[0008] It is intended that the gas mixture consists of 60% CO2, 35% 02 and 5% 03. Further, the gas mixture may be pumped into the operating space from a high-pressure storage tank.
[0009] The method may further comprise that at least one sound source is provided within the operating space and sound waves emitted from the sound source may be synchronized with the heart frequency of the patient, wherein the ratio between heart frequency Y and sound waves is Y/8, Y/4, Y/2, Y/1 and Yx2.
[0010] The operating space may be a capsule or cabin, wherein the respective dimensions can be adapted to the patient's needs.
[0011] The operating space may be formed as an inflatable sack or bag having at least one compai Unent for encapsulating the patient.
[0012] The gaseous mixture may be released into the environment after the treatment.
[0013] It is further intended that the composition of the gas mixture be constantly checked during the treatment.
[0014] The composition of the gas mixture shall be constantly kept in the desired range.
[0015] The disease, which is to be treated shall be selected from the group comprising Diabetes Mellitus and cardiovascular diseases comprising diseases of the heart and blood vessels comprising conditions such as aortic stenosis, high blood pressure, coronary heart disease or ischaemic heart disease, cerebrovascular disease or stroke, heart failure, rheu-matic heart disease and hypertension.
[0016] Another object of the present disclosure is a device for carrying out the treatment of diseases, wherein the device comprises an operating space for encapsulating at least one patient's body excluding the head, at least one sound sensor and one sound-source con-nected to a control unit and further a controllable inlet and sensor for a gaseous mixture used for the treatment, wherein the gaseous mixture comprises a pre-defined ratio of CO2 and 03 and a controllable valve is located between the source of the gaseous mixture and a buffer tank, which is connected through a second controllable valve with a vacuum pump that is connected with the inside of the operating space and wherein the operating space comprises a gas detector and a control unit for operating the controllable valves and the vacuum pump to adjust the ratio of the components of the gaseous mixture, the pressure and time period for applying the gaseous mixture to the operating space as well as for controlling the frequency of the sound waves.
[0017] The device may be a capsule or cabin and the respective dimensions of the operat-ing space may be adjusted to the patient's needs. The term "dimensions" comprises width, length and height as well as dimensions of any necessary openings, e.g. for the neck of a patient so that the patient's head is outside of the operating space.
[0018] The detector for the composition of the gaseous mixture can be a CO2 saturation detector.
Summary of the figures
[0019] The invention will now be described on the basis of figures. It will be understood that the embodiments and aspects of the invention described in the figures are only exam- pies and do not limit the protective scope of the claims in any way. The invention is de-fined by the claims and their equivalents. It will be understood that features of one aspect or embodiment of the invention can be combined with a feature of a different aspect or aspects of other embodiments of the invention. It shows: [0020] Figure 1 Schematic block diagram to perform the disclosed method
Detailed description of the invention
[0021] The present invention provides a method and a device for the treatment of diseas-es.
[0022] The term "cardiovascular diseases" shall refer to diseases of the heart and blood vessels comprising conditions such as aortic stenosis, high blood pressure, coronary heart disease or ischaemic heart disease, cerebrovascular disease or stroke, heart failure, rheu-matic heart disease and hypertension.
[0023] Diabetes Mellitus generally refers to fasting plasma glucose values of >126 mg/dL (> 7 0 mmo1/1) and insulin resistance is defined here as a fasting blood insulin level 25 greater than 20 mcU/mL [0024] On one hand, the method of the instant disclosure refers to a ozone therapy combined with acoustic treatment, which comprises a. forming of a closed but opening operating space with a sound-source for at least one patient, b. a method to introduce the mixture of CO2 and 03 gases into the operating space comprising at least one patient inside the operating space, c. a method to keep the gas mixture inside the operating space for a predetermined time period, and d. drawing of the gas mixture from the operating space after the treatment.
[0025] On the other hand, the instant disclosure refers to a device which can be used in a combination of a acoustic-ozone therapy with CO2, therapy, which comprises a. an "operating space" (sack, cabin) for at least one patient, b. an opening which controllably connects the inner and the outer space, c. at least one source of the gaseous agent used for the treatment, d. a conveying device for the agent from the source into the operating space, e. a control unit controlling the conveying device,fl at least one sensor and one sound-source connected to the control unit.
[0026] The suggested therapy for carrying out the set task, on the one hand, is a method of an ozone therapy including a) the treatment of a patient from the neck down in a closed but opening operating space, 17) the method to get the therapeutic mixture of CO2 and 03 gases into the operating space when at least one patient is inside from the waist down, c) the method to keep the mixture inside for a pre-determined period 6.0 the drawing of the gas mixture from the operating space after the treatment. In one of the implementations the gas mixture is 80-95% CO2 and 0.1 5% 03, or the composition of the mixture is constantly kept changing and given the basic CO2 concentration the maximum 03 concen-tration (1.5 -5%) is gradually reached by ionisation. The pressure in the operating space is kept between 0.5 -1.5 bars.
[0027] On the other hand, the set task was carried out by using a device to apply ozone therapy, which includes a) an operating space for at least one patient, b) an opening which controllably connects the inner and the outer space, c) at least one source of the gaseous agent used for the treatment, a CO2 source and an 03 source (ionising unit) d) a conveying device for the agent from the source into the operating space, e) a control unit controlling -ti-the conveying device and at least one sensor connected to the control unit. There is a controllable valve between the gas source and the operating space, which is, through another valve, connected to a vacuum pump. The control unit is based on micro control.
[0028] Some advantageous implementations of both the methods and the device are de-scribed in the dependent claims.
[0029] The efficient daily therapy in the operating space is 20 -40 minutes long for 20-30 consecutive days. Drawing the air from it and increasing the pressure to 0.1-1.5 bars by injecting a CO2/03 gas mixture can decrease the pressure in the operating space.
[0030] The invention depicted in the technical drawings is described in detail. Figure lshows a block diagram of the finally accomplished shape of the device can be seen.
[003 t] The desired or changing composition of the gas mixture can be directly aimed with higher pressure at the legs through a flexible system within the covering. CO2 (80%) can be gained from high pressure cartridges while 03 (1-5%) can be made through ionization. In the latter case the gas/air change under the covering must be secured. The sequencing and the periods of the gases to be used are determined in ad-vance considering both the desired results and the health conditions of the patient. In the closed box stereos are placed with magnets radiating the legs plus the control electronics, the gas pumps and the valves.
[0032] The pulse of the patient is Y so the treatment frequencies are Y/8, Y/4, Y/2, Y/1 for 3 minutes each and than Yx2 for 8 minutes.
[0033] The state of the art science says that arteriosclerosis is irreversible. This new invention, however, makes the wall of veins demonstrably more flexible.
[0034] The sound therapy rises the endothelin level, which signals vasodilatory effect, that is, the broadening of the veins while the 1L-8 level goes down meaning anti-inflammatory and analgesic effect. It improves the permeability and flexibility of the arteries, the circula-tion in the capillaries. The temperature of the limbs rises while the walking range of the patient increases.
[0035] Folk medicine used to apply leeches to gangrenous wounds. The suction of the leeches often started up the circulation in the capillaries and this has lent the idea that suction combined with extra pressure can provide an ever more efficient treatment for patients suffering from stenosis with special respect to limbic stenosis.
[0036] Healing is grounded on a proper oxygen supply of the tissues. It is one of the basic rules of nature. Blood has three main constituents, white blood cells, playing an important role in the defence against infections, red blood cells, transporting oxygen and finally plasma, transporting both the white and the red blood cells. In normal case it is only the red blood cells that transport oxygen, however, in the case of any circulatory disorders red blood cells often stick together inhibiting circulation in the capillar-ies as well as decreasing oxygen absorption.
[0037] Due to the vacuum applied as part of the therapy the blood supply of both the upper and the lower layer of the skin will be increased. Vacuum stimulates the body tp release histamine so that veins and arteries expand increasing the throughput. Blood and lymphatic circulation in the limbs will speed up decreasing the level of prostaglan-dins that cause pain. By stimulating the sensory nerves, analgesic (pain killing) chemicals are released. Vacuum also activates the cells responsible for the production of flexible fibres in the connective tissue. As a result, the skin gets much tighter and elastic.
[0038] The CO2/03 gas mixture diffuses into the skin and gets into the cells. Primarily, CO? has a specific vasodilatory effect in the limbs, secondarily; it evolves a beneficial effect on the operation of the heart in general. Ozone separates blood cells that are stuck together and thus restores the oxygen transport capacity. The oxygen supply of the tissues increases, on the one hand, because of the increased pressure in the arteries, on the other hand, because of the decreased viscosity of the blood. Ozone oxidises de-posits on the vessel walls thus cleaning them and quickening oxygen metabolism. It also stimulates the formation of ATP and some of the cleaning enzymes that protect the cell walls and through the production of interferon the immune system is boosted as well.
[0039] This affects the arteries, the veins and the lymphatic system as well, and not only the skin but also the internal organs are included.
[0040] As a result of the increased oxygen concentration, even despite the poorer circulation, a significant amount of oxygen gets to the damaged cells and tissues. Because of the improved oxygen supply the metabolism of the cells significantly increases so the deposits accumulated are transported inhibiting the risk of infection while enhancing and facilitating natural healing processes. Another benefit of this therapy is the antibacterial effect of ozone playing a major role in fighting infections. The third important interest of the therapy is the diffusion caused by high pressure that starts up circulation even in capillaries where circulation has already stopped.
[0041] The synergies of these three effects result in the distinct improvement of blood circulation in general.
[0042] The state of the art science teaches that arteriosclerosis is irreversible. The dis-closed invention, however, makes the wall of veins demonstrably more flexible.
[0043] Our research shows positive changes in the decreased systolic figures and both in the increased pulse pressure and the flexibility of the arteries. According to our results, the aorta and the large vessels all reacted positively to the treatment, which meant that the same amount of blood ejected from the heart more efficiently got to the periph-eries.
[0044] Our research shows definite increase in three fields: the number of capillaries in general, the diffusion surface of the muscles and the concentration of respiratory enzymes in the muscle tissues.
Examples
[0045] 10 men and 10 women with the age breakdown shown in Table 1 took part in a program for testing the method. The patients were treated with the disclosed method for six weeks between a first and a second testing. The study analyses the differences in the results of the two tests regarding the systolic and diastolic figures, the pulse-pressure figures and the changes in the average of the artery-flexibility figure.
Age (years) Men Women Total 45-55 2 1 3 55-65 4 3 7 65-75 4 6 10 TOTAL 10 10 20
[0046] Table 1
[0047] The differences between both the systolic and the diastolic average pressure are significant, independent of both age and gender. The differences in the average pulse pressure in all three age groups and in the case of both genders have significantly dropped as a result of the treatments. The averages characterising the flexibility of the big artery (AST) significantly dropped, too, independent of gender in all three groups.
[0048] Our research proves positive changes in the decreased systolic pressure and both in the increased pulse-pressure and the flexibility of the arteries. The decrease of AST is a result of the increased flexibility of the veins, arteries and vessels.
Claims (1)
- Claims 1 A method for the treatment of diseases, comprising the steps of: using an operating space for encapsulating at least one patients body excluding the head; providing a gas mixture of CO2 and 03 into the operating space encapsulating the patient, wherein the gas mixture consists of 80 -89% CO2 and 0.1 - 5.0 % 03 adding the respective amount of 02 up to 100%; keeping the pressure in the operating space between 0.5 -1.5 bar; pumping the gas mixture into the operating space at the rate of 0.4 1.2 li-tres per second; keeping the gas mixture inside the operating space for a pre-determined pe-Hod of time. 2. 3. 6.The method of claim 1, wherein the gas mixture consists of 60% CO2, 35% 02 and 5% 03.The method of claim 1 or 2, wherein the gas mixture is pumped into the operating space from a high pressure storage tank.The method of one of claims 1 to 3, wherein the pre-determined time period for applying the gaseous mixture is between 20 -40 min for a maximum of 20 -30 con-secutive days.The method of one of claims 1 to 4, wherein at least one sound source within the operating spaceis provides and sound waves emitted from the sound source are synchronized with the heart frequency of the patient, wherein the ratio between heart frequency Y and sound waves is Y/8, Y/4, Y/2, Y/1 and Yx2.The method of one of claims 1 to 5, wherein the operating space is a capsule or cabin.7. The method of one of claims 1 to 6, wherein the operating space is formed as an inflatable sack or bag having at least one compartment for encapsulating the patient.8. The method of one of claims I to 7,wherein the gas mixture is released into the en-vironment after the treatment.9. The method of one of claims I to 8, wherein the composition of the gas mixture is constantly checked during the treatment.10. The method of one of claims 1 to 9, wherein the composition of the gas mixture is constantly kept in the desired range.11. The method of one of claims 1 to 10, wherein the disease is selected from the group comprising Diabetes Mellitus and cardiovascular diseases comprising diseases of the heart and blood vessels comprising conditions such as aortic stenosis, high blood pressure, coronary heart disease or ischaemic heart disease, cerebrovascular disease or stroke, heart failure, rheumatic heart disease and hypertension.12. A device for carrying out the treatment of diseases, wherein the device comprises an operating space for encapsulating at least one patient's body excluding the head, at least one sound sensor and one sound-source connected to a control unit and further a controllable inlet and sensor for a gaseous mixture used for the treatment, wherein the gaseous mixture comprises a pre-defined ratio of CO2 and 03 and a controllable valve is located between the source of the gaseous mixture and a buffer tank, which is connected through a second controllable valve with a vacuum pump that is connected with the inside of the operating space and wherein the operating space comprises a gas detector and a control unit for operating the controllable valves and the vacuum pump to adjust the ratio of the components of the gaseous mixture, the pressure and time period for applying the gaseous mixture to the oper-ating space as well as for controlling the frequency of the sound waves.13. The device of claim 12, wherein operating space is a capsule or cabin.14. The device of claim 13, wherein the respective dimensions of the operating space are adjusted to the patient to be treated.15. The device of claim 14, wherein the detector for the composition of the gaseous mixture is a CO2 saturation detector.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1500555.6A GB2534153A (en) | 2015-01-14 | 2015-01-14 | Method and device for the treatment of diseases |
| PCT/EP2016/050609 WO2016113325A1 (en) | 2015-01-14 | 2016-01-14 | Machine for a joint pulsed sound magnetic-ozone-co2 therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1500555.6A GB2534153A (en) | 2015-01-14 | 2015-01-14 | Method and device for the treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201500555D0 GB201500555D0 (en) | 2015-02-25 |
| GB2534153A true GB2534153A (en) | 2016-07-20 |
Family
ID=52597564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1500555.6A Withdrawn GB2534153A (en) | 2015-01-14 | 2015-01-14 | Method and device for the treatment of diseases |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2534153A (en) |
| WO (1) | WO2016113325A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11439553B2 (en) | 2018-05-09 | 2022-09-13 | André Hugo Smith | Multimodal device for transdermal treatments |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN203017269U (en) * | 2012-07-19 | 2013-06-26 | 邹平起 | Natural recovery treatment equipment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2070503A5 (en) * | 1969-12-08 | 1971-09-10 | Oullier Yves | |
| US20120065576A1 (en) * | 2007-08-14 | 2012-03-15 | Stryker Corporation | Drug delivery system |
| CN102974043A (en) * | 2011-09-07 | 2013-03-20 | 国发科技（大连）有限公司 | Health medical apparatus |
| JP6081767B2 (en) * | 2011-10-25 | 2017-02-15 | 諒 黒沢 | Treatment device |
| CN104161664A (en) * | 2014-09-03 | 2014-11-26 | 何水英 | Full-function health maintenance conditioning instrument |
-
2015
- 2015-01-14 GB GB1500555.6A patent/GB2534153A/en not_active Withdrawn
-
2016
- 2016-01-14 WO PCT/EP2016/050609 patent/WO2016113325A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN203017269U (en) * | 2012-07-19 | 2013-06-26 | 邹平起 | Natural recovery treatment equipment |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201500555D0 (en) | 2015-02-25 |
| WO2016113325A1 (en) | 2016-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9078982B2 (en) | Systems, methods and devices for circulatory access | |
| Földi et al. | Conservative treatment of lymphoedema of the limbs | |
| US11642274B2 (en) | Method for treating organic erectile dysfunction | |
| JP5913468B2 (en) | Method and apparatus for gas supply during cardiopulmonary resuscitation | |
| ATE176761T1 (en) | DEVICE FOR DRUG ADMINISTRATION IN BLOOD VESSELS | |
| Soran et al. | Enhanced external counterpulsation in the management of patients with cardiovascular disease | |
| US7517312B2 (en) | External counter pulsation treatment | |
| Xinqiang et al. | Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate | |
| GB2534153A (en) | Method and device for the treatment of diseases | |
| RU2745759C1 (en) | Method for treatment of acute pulmonary insufficiency and device for its implementation savelieva b.s. | |
| Yilmaz et al. | Optimal ventilator settings in acute lung injury and acute respiratory distress syndrome | |
| Clarke-Moloney et al. | A review of technological approaches to venous ulceration | |
| US8128550B2 (en) | External counter pulsation treatment | |
| RU2308930C2 (en) | Method for early sanatorium-health resort rehabilitation in patients after surgical therapy of ischemic cardiac disease | |
| Nahas et al. | Circulation in dogs after respiratory arrest induced by curare | |
| RU2465843C1 (en) | Method of adjuvant therapy of locally advanced stomach cancer | |
| US20180001068A1 (en) | Method of oxygen saturation for wound treatment | |
| RU2264815C2 (en) | Method for treating localized scleroderma | |
| RU2179853C1 (en) | Method for preventing and treating the cases of angio- and neuropathies concomitant to diabetes mellitus | |
| WO2019073286A1 (en) | A device enhancing the blood circulation at theextremities using compressed carbon dioxide-saturated water | |
| US20230031211A1 (en) | Ultrafine oxygenated nanobubbles hydrotherapy | |
| SU1050705A1 (en) | Method of treating patients ill with obliterating endarteritis | |
| RU2464009C1 (en) | Method of treating patients with chronic lymphovenous insufficiency of lower extremities | |
| RU2077892C1 (en) | Method for treating recidivating pulmonary edema | |
| RU2324497C2 (en) | Method of re-perfusion therapy in acute myocardial infarction with elevated st |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |